Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia

BMJ Open

Volumn 2, Issue 5, 2012, Pages

  Ford, Emily ^a   Adams, Jon ^a,b   Graves, Nicholas ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CRATAEGUS EXTRACT;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DETERIORATION; DISEASE CLASSIFICATION; ECONOMIC DECISION MODEL; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION COST; HUMAN; MEDICAL LITERATURE; MODEL; MORTALITY; NEW YORK HEART ASSOCIATION CLASSIFICATION; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW;

EID: 84866440373     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001094     Document Type: Article

References (42)

1. Krum H, Stewart S. Chronic heart failure: time to recognise this major public health problem. Med J Aust 2006;184:147-8.
2. McLean AS, Eslick GD, Coats AJS. The epidemiology of heart failure in Australia. Int J Cardiol 2007;118:370-4. (Pubitemid 46678240)
3. Agvall B, Borgquist L, Foldevi M, et al. Cost of heart failure in Swedish primary healthcare. Scand J Prim Health 2005;23:227-32. (Pubitemid 43378941)
4. Australian Institute of Health and Welfare. Heart failure: what of the future? Cat. No. AUS 34. Canberra: AIHW, 2003.
5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006, 2006.
6. Krum H, Jelinek MV, Stewart S, et al. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia in 2006. Med J Aust 2006;185:549-56. (Pubitemid 44816942)
7. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 2007;6:127-39. (Pubitemid 46758752)
8. Quinn B. Pharmacological treatment of heart failure. Crit Care Nurs Q 2007;30:299-306. (Pubitemid 47415122)
9. Furey A, Tassell M. Towards a scientific approach in the assessment of efficacy of an herbal preparation: hawthorn (Crataegus spp.). Eur J Heart Fail 2008;10:1153-7.
10. Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. Forsch Komp Klas Nat 2004;11:36-9. (Pubitemid 39279368)
11. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomised trials. Am J Med 2003;114:665-74. (Pubitemid 36703236)
12. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure (Review). Cochrane Database Syst Rev 2009; (1). Art No: CD005312. doi: 10.1002/14651858.CD005312.pub2.
13. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. J Health Serv Res Po 2008;13:23-30.
14. Kymes S. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. Ophthal Epidemiol 2008;15:76-83. (Pubitemid 351574435)
15. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27. (Pubitemid 27296586)
16. Spencer M, Briggs A, Grossman R, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005;23:619-37. (Pubitemid 40994129)
17. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999;159:1690-700. (Pubitemid 29379130)
18. Yao G, Freemantle N, Flather M, et al. Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. Pharmacoeconomics 2008;26:879-89.
19. Miller G, Randolph S, Forkner E, et al. Long-term cost-effectiveness of disease management in systolic heart failure. Med Decis Making Online First 2009.
20. Yao G, Freemantle N, Calvert M, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007;28:42-51. (Pubitemid 46134956)
21. Canter P, Thompson-Coon J, Ernst E. Cost effectiveness of complementary treatments in the United Kingdom: a systematic review. Br Med J 2005;331:880-1. (Pubitemid 41502711)
22. Dalziel K, Segal L, Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness? Cost Eff Resour Alloc 2008;6:9.
23. Thompson T, Feder G. Complementary therapies and the NHS: uncertain evidence of cost effectiveness should not exclude complementary medicine from reviews and guidelines. Br Med J 2005;331:856-7.
24. Herman P, Craig B, Caspi O. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. BMC Complem Altern M 2005;5:11.
25. Hollinghurst S, Sharp D, Ballard K, et al. Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain: economic evaluation. Br Med J Online First 2008;337:a2656.
26. Kim N, Yang B, Lee T, et al. An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov model decision analysis. BMC Complem Altern M 2010;10:274.
27. Flather M, Shibata M, Coats A, et al. Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elederly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. (Pubitemid 40222359)
28. Muntwyler J, Abetel G, Gruner C, et al. One-year mortality among unselected outpatients with heart failure. Eur Heart J 2002;23:1861-6. (Pubitemid 35398055)
29. Holubarsch CJF, Colucci WS, Meinertz T, et al. Survival and prognosis: investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) - rationale, study design and study protocol. Eur J Heart Fail 2000;2:431-7. (Pubitemid 32003342)
30. Zick S, Gillespie B, Aaronson K. The effect of Crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail 2008;10:587-93.
31. Zick S, Vautaw B, Gillespie B, et al. Hawthorn extract randomised blinded chronic heart failure (HERB-CHF) trial. Eur J Heart Fail 2009;11:990-9.
32. Cowper PA, DeLong ER, Whellan DJ, et al. Economic effects of beta-blocker therapy in patients with heart failure. Am J Med 2004;116:104-11. (Pubitemid 38056663)
33. Victorian Department of Health. Victorian health services policy and funding guidelines 2010-11 technical guidelines. Melbourne: Victorian Department of Health, 2010.
34. Queensland Health. Casemix funding model 2008-2009: component prices summary. Brisbane: Queenland Government, 2008.
35. Australian Government Department of Health and Ageing. Medicare Benefits Schedule (MBS) online. Canberra: Australian Government Department of Health and Ageing, 2010.
36. Holubarsch CJF, Colucci WS, Meinertz T, et al. The efficacy and safety of crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008;10:1255-63.
37. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. Canberra: Australian Government Department of Health and Ageing, 2010.
38. Australian Bureau of Statistics. 3302.0 - Deaths, Australia, 2008.
39. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press, 2007.
40. Koller M, Lorenz W, Aubke W, et al. Crataegus special extract WS 1442 in the treatment of early stages of CHD-associated heart failure. MMW Fortschr Med 2006;148:42.
41. Gohler A, Geisler BP, Manne J, et al. Utility estimates for decision-analytic modelling in chronic heart failure: health states based on New York heart association classes and number of rehospitalisations. Value Health 2009;12:185-7.
42. Turner D, Raftery J, Cooper K, et al. The CHD challenge: comparing four cost-effectiveness models. Value Health 2011;14:53-60.